CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB-IIIA NSCLC

By afschroeder • August 14, 2025

Lee JM, Pujol JL, Zhang J, Leonov O, Tsuboi M, Kim ES, Ng C, Moreno-Mata N, Cummings A, Hacibekiroglu I, Sehitogullari A, Veeramachaneni N, Spillane C, Duan J, Bossen C, Savchenko A, Lobetti-Bodoni C, Mok T, Garrido P. CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB-IIIA NSCLC. JTO Clin Res Rep. 2025 Jun 13;6(8):100859. doi: 10.1016/j.jtocrr.2025.100859. PMID: 40810132; PMCID: PMC12343357.

Tags: Hematology/Oncology, Monoclonal antibodies, neoadjuvant treatment, NSCLC, Publications, Pulmonary, Critical Care & Sleep Medicine

Mirvetuximab Soravtansine Exposure and Incidence of Cataract Surgery

Silverstein JF, Smick A, Tsui E, Alomaja O, Johnson B, Tseng CH, Salani R, Slamon DJ, Chase DM, Konecny GE. Mirvetuximab Soravtansine Exposure and Incidence[...]

Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3

Nooka AK, Strouse C, Larson SM, Lesokhin A, Varshavsky-Yanovsky A, Vesole DH, Koehne G, Soussou E, Sullivan ST, Cheng J, Raje N. Efficacy and safety[...]

Five-Year Survival with Tebentafusp in Metastatic Uveal Melanoma

Piperno-Neumann S, Rutkowski P, Hassel JC, Butler MO, Schlaak M, Sullivan RJ, Dummer R, Kirkwood JM, Sacco JJ, Shoushtari AN, Piulats JM, Salama AKS, Orloff[...]